Bimzelx® targets interleukin-17 (IL-17), one of the key chemical hormones that are elevated in people who have psoriasis. We now know that psoriasis is driven by underlying and excessive inflammation, and IL-17 is one of the critical entities involved in this process.
In clinical trials, an astounding 7 out of 10 subjects achieved 100% clearance of their psoriasis within 16 weeks. Clear or almost clear skin was reached in over 90% of subjects. Improvement was noted rapidly, with an incredible 3 out 4 subjects improving by at least 75% within 4 weeks. Common side effects included uncomplicated cold symptoms, yeast infection, cold sores, headache, fatigue and mild dyspepsia (i.e., upset stomach).
Bimzelx® is administered by subcutaneous injection at home after proper training. The frequency of doses is every 4 weeks for the first 4 months, then every 8 weeks thereafter. Injection site reactions can occur, but are mild and typically self-limited.
Bimzelx® joins 11 other biologic therapies available to treat psoriasis. It is an evolving and exciting time, and our Psoriasis Treatment Center in Boston has never been more equipped to help patients manage this disease. If you are suffering from plaque psoriasis, book a consultation with one of our expert dermatologists to find out if Bimzelx® is right for you.